Saving Seafood

For Your Heart, Eat Fish Or Take Pills? Now There’s A Drug Equal To 8 Salmon Servings

November 25, 2019 — It’s long been known that eating fish — especially cold-water fish such as salmon that are rich in omega-3 fatty acids — is good for heart health.

But, for the millions of Americans who are at high risk of heart disease, eating enough fish to make a difference isn’t likely to be realistic for most.

There’s growing evidence that taking a very high dose of purified fish oil, delivered in a prescription pill, can help prevent heart attacks and strokes among people who have elevated risks. The amount of fish oil in the daily recommended dose of the pill is the equivalent of eating about eight to 10 servings of salmon a day.

In early November, an advisory panel to the FDA voted unanimously to approve expanded use of the prescription drug, Vascepa, which is made from one type of omega-3 fatty acid, called eicosapentaenoic acid, or EPA for short. The oil is extracted from sardines and anchovies, and then purified.

Currently, Vascepa is already approved for use in people with very high levels of triglycerides — which is a type of fat in the blood. (You can check your triglycerides as part of a cholesterol screening.)

Read the full story at NPR

FDA panel endorses wider use of fish-oil drug to protect against heart problems

November 15, 2019 — A panel of experts unanimously recommended Thursday that the Food and Drug Administration allow wider use of a fish oil-based drug to treat people at high risk for heart attacks and strokes even when they are taking cholesterol-lowering drugs.

The 16-0 endorsement of the FDA advisory committee puts Dublin-based Amarin Corp. one step closer to widespread distribution of Vascepa, a drug the company has said could be worth billions of dollars annually. The FDA, which usually follows such guidance, could make a long-awaited final decision next month.

“There’s a definite need for additional therapeutic approaches,” said Kenneth D. Burman, chief of the endocrine section at MedStar Washington Hospital Center, who chaired the panel. Despite some side effects, he said, “this seems a very useful new agent for addition to the armamentarium for the treatment of these patients.”

The drug, a purified version of the Omega-3 fatty acid found in fish, is aimed at some of the more than 40 million people in the U.S. who take statins to control their LDL, or “bad” cholesterol, and have adopted lifestyle changes, yet remain at risk of cardiovascular problems because of elevated triglyceride levels.

Triglycerides are another type of fat in the blood. When their levels are too high, generally more than 200 milligrams per deciliter of blood, the result can be deaths, heart attacks, strokes, unstable angina or the need for cardiac surgery.

A landmark 2018 study, led by a researcher at Brigham and Women’s Hospital and sponsored by Amarin, showed that patients who took four grams of Vascepa daily fared 25 percent better in staving off those events than those given a placebo. The researchers spent more than six years following more than 8,000 middle-aged and older patients in 11 countries who had coronary artery disease or diabetes and at least one other risk factor, such as high blood pressure.

Read the full story at The Washington Post

New study suggests fish oil derivative may benefit heart health

March 19, 2019 — New numbers suggest that a purified fish oil derivative, a prescription drug called Vascepa, is more effective at preventing cardiovascular events than previously thought.

The drug lowered the rate of these events in high-risk patients — including strokes, heart attacks and deaths from cardiovascular causes — by 30% overall versus placebo, according to a study published Monday in the Journal of the American College of Cardiology.

This is better than previously thought because because the study authors took into account not just first cardiovascular events as before, but also second, third, fourth events, and so on. Earlier results were announced by Irish drugmaker Amarin Pharma in September and then in a study released November in the New England Journal of Medicine.
“By looking only at first events, we underestimate the true underlying treatment benefit offered,” study author Dr. Deepak L. Bhatt said in a statement Monday.

“With this drug, we are not only preventing that first heart attack but potentially the second stroke and maybe that third fatal event,” said Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School.

According to these latest data on cardiovascular episodes, Vascepa slashed first events by a quarter, second and third events by more than 30%, and later events by almost a half. The researchers estimated that by treating a thousand patients for five years, they could prevent 76 coronary revascularizations, 42 heart attacks, 14 strokes, 16 hospitalizations due to unstable angina and 12 deaths related to cardiovascular causes.

Read the full story at CNN